| Identification | Back Directory | [Name]
PAI-1 | [CAS]
NoCAS | [Synonyms]
PAI-1
ARMAPE
PAI-1, RAT
MOUSE PAI-1
PAI-1, HUMAN
PAI-1, MOUSE
PAI-1, MUTANT, MOUSE
PLASMINOGEN ACTIVATOR INHIBITOR 1
PLASMINOGEN ACTIVATOR INHIBITOR-1, RAT
MOUSE PLASMINOGEN ACTIVATOR INHIBITOR-1
PLASMINOGEN ACTIVATOR INHIBITOR-1, HUMAN
PLASMINOGEN ACTIVATOR INHIBITOR-1, MUTANT, MOUSE
PLASMINOGEN ACTIVATOR INHIBITOR-1, RAT, RECOMBINANT
PLASMINOGEN ACTIVATOR INHIBITOR-1, HUMAN, RECOMBINANT
PLASMINOGEN ACTIVATOR INHIBITOR-1, MUTANT, MOUSE, RECOMBINANT
Plasminogen Activator Inhibitor Type 1, Mouse Assay Kit, BioAssay&trade
Plasminogen Activator Inhibitor Type 1, active, Rat Assay Kit, BioAssay&trade
Plasminogen Activator Inhibitor Type 1, active, Mouse Assay Kit, BioAssay&trade
Plasminogen Activator Inhibitor Type 1, active, Human, Assay Kit, BioAssay&trade
Plasminogen Activator Inhibitor Type 1, active, Rabbit Assay Kit, BioAssay&trade
Plasminogen Activator Inhibitor Type 1, active, Porcine Assay Kit, BioAssay&trade | [Molecular Formula]
C27H47N9O9S | [MDL Number]
MFCD00080197 | [MOL File]
MFCD00080197 | [Molecular Weight]
673.78 |
| Hazard Information | Back Directory | [Biological Activity]
Cell permeable: no''Primary Target
Tissue plasminogen activator (tPA) and urokinase (uPA)''Product does not compete with ATP.''Reversible: no | [Enzyme inhibitor]
This 402-residue serine protease inhibitor, or serpin (MW = 45074 g/mol; Abbreviation: PAI-1) binds to and inhibits plasminogen activators-tissuetype plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This inhibition reduces plasmin production and suppresses dissolution of fibrin clots. Elevated PAI-1 levels correlate with an increased cardiovascular disease risk, a behavior that has also been linked to obesity and metabolic syndrome. Pharmacological suppression of PAI-1 is a likely way to prevent or treat vascular disease. Reduced PAI-1 levels may result in increased fibrinolysis and an associated bleeding diathesis. PAI-1 was initially identified in the 1980s, and the first reported case of PAI-1 deficiency appeared in 1989. Unambiguous proof that PAI-1 deficiency as a cause of a bleeding disorder has been rare, but use of selective PAI inhibitors (See PAI-749) may clarify this point. Because of lack of standardized commercially available PAI-1 activity assay sensitive in the lowest range, the true prevalence of this rare condition has yet to be established. |
|
| Company Name: |
BioVendor R D
|
| Tel: |
420-549124185 |
| Website: |
www.biovendor.com |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|